Characteristics of included studies
| Author(s) . | Setting (n)∗ . | Population, n∗ . | Rapid assay(s) . | Reference standard assay(s) . |
|---|---|---|---|---|
| Beranger et al18 | France (539) | iTTP, 328 cTTP, 18 Other TMA, 156 | HemosIL AcuStar | In-house FRETS-VWF73 assay |
| Braf et al13 | Sweden (43) | NS | Technoscreen | Commercial ELISA (Technozym) |
| Dimopoulos et al17 | Denmark (706) | iTTP, 311 cTTP, 0 HUS, 43 HELLP, 14 Other, 162 | HemosIL AcuStar | In-house FRETS-VWF73 assay |
| Falcinelli et al31 | Italy (46) | iTTP, 46 | HemosIL AcuStar | Commercial ELISA (Technozym) |
| Favaloro et al32 | Australia (733) | iTTP, 217 HUS, 18 HELLP, 6 | HemosIL AcuStar | Commercial ELISA (Technozym) |
| Favresse et al12 | Belgium (38) | iTTP, 8 | HemosIL AcuStar | Commercial ELISA (Technozym) |
| Foxton et al33 | United Kingdom (110) | NS | HemosIL AcuStar, Technofluor FRET | Commercial ELISA (Technozym) |
| Fretwell et al34 | United Kingdom (205) | iTTP, 126 cTTP, 4 Other, 75 | HemosIL AcuStar | Commercial ELISA (Technozym) |
| Fretwell et al35 | United Kingdom (142) | NS | Technofluor FRET | Commercial ELISA |
| Irsara et al36 | Austria (32) | iTTP, 14 Other TMA, 1 Other, 16 | HemosIL AcuStar, Technofluor FRET | ACTIFLUOR FRETS-VWF73 assay |
| Mancini et al37 | Italy (130) | iTTP, 120 cTTP, 3 Other TMA, 6 Other, 1 | HemosIL AcuStar | In-house FRETS-VWF73 assay |
| Moore et al38 | Multinational (253) | NS | Technoscreen | Commercial ELISA (Technozym), in-house FRETS-VWF73 assay |
| Pascual et al39 | Multinational (221) | iTTP, 113 cTTP, 7 HUS, 16 Other TMA, 91 Other, 2 | HemosIL AcuStar | In-house FRETS-VWF73 assay, commercial ELISA (Technozym), DG-EIA |
| Pitchford, in press† | United Kingdom (716) | iTTP, 49 cTTP, 2 | HemosIL AcuStar | Commercial ELISA |
| Singh et al14 | Multinational (94) | iTTP, 70 cTTP, 1 Other TMA, 19 Other, 4 | HemosIL AcuStar, Technofluor FRET | FRETS-VWF73 assays, commercial ELISA (Technozym) |
| Stephenson et al20 | Australia (80) | iTTP, 20 | Technoscreen | Commercial ELISA (Technozym) |
| Stratmann et al40 | Germany (10) | iTTP, 8 HUS, 1 Other, 1 | HemosIL AcuStar | Commercial ELISA (Technozym) |
| Toulon et al41 | France (56) | NS | HemosIL AcuStar | FRETS-VWF73 assay |
| Valsecchi et al42 | Italy (127) | iTTP, 100 cTTP, 9 HUS, 7 Other TMA, 11 | HemosIL AcuStar | In-house FRETS-VWF73 assay, commercial ELISA (Technozym) |
| Author(s) . | Setting (n)∗ . | Population, n∗ . | Rapid assay(s) . | Reference standard assay(s) . |
|---|---|---|---|---|
| Beranger et al18 | France (539) | iTTP, 328 cTTP, 18 Other TMA, 156 | HemosIL AcuStar | In-house FRETS-VWF73 assay |
| Braf et al13 | Sweden (43) | NS | Technoscreen | Commercial ELISA (Technozym) |
| Dimopoulos et al17 | Denmark (706) | iTTP, 311 cTTP, 0 HUS, 43 HELLP, 14 Other, 162 | HemosIL AcuStar | In-house FRETS-VWF73 assay |
| Falcinelli et al31 | Italy (46) | iTTP, 46 | HemosIL AcuStar | Commercial ELISA (Technozym) |
| Favaloro et al32 | Australia (733) | iTTP, 217 HUS, 18 HELLP, 6 | HemosIL AcuStar | Commercial ELISA (Technozym) |
| Favresse et al12 | Belgium (38) | iTTP, 8 | HemosIL AcuStar | Commercial ELISA (Technozym) |
| Foxton et al33 | United Kingdom (110) | NS | HemosIL AcuStar, Technofluor FRET | Commercial ELISA (Technozym) |
| Fretwell et al34 | United Kingdom (205) | iTTP, 126 cTTP, 4 Other, 75 | HemosIL AcuStar | Commercial ELISA (Technozym) |
| Fretwell et al35 | United Kingdom (142) | NS | Technofluor FRET | Commercial ELISA |
| Irsara et al36 | Austria (32) | iTTP, 14 Other TMA, 1 Other, 16 | HemosIL AcuStar, Technofluor FRET | ACTIFLUOR FRETS-VWF73 assay |
| Mancini et al37 | Italy (130) | iTTP, 120 cTTP, 3 Other TMA, 6 Other, 1 | HemosIL AcuStar | In-house FRETS-VWF73 assay |
| Moore et al38 | Multinational (253) | NS | Technoscreen | Commercial ELISA (Technozym), in-house FRETS-VWF73 assay |
| Pascual et al39 | Multinational (221) | iTTP, 113 cTTP, 7 HUS, 16 Other TMA, 91 Other, 2 | HemosIL AcuStar | In-house FRETS-VWF73 assay, commercial ELISA (Technozym), DG-EIA |
| Pitchford, in press† | United Kingdom (716) | iTTP, 49 cTTP, 2 | HemosIL AcuStar | Commercial ELISA |
| Singh et al14 | Multinational (94) | iTTP, 70 cTTP, 1 Other TMA, 19 Other, 4 | HemosIL AcuStar, Technofluor FRET | FRETS-VWF73 assays, commercial ELISA (Technozym) |
| Stephenson et al20 | Australia (80) | iTTP, 20 | Technoscreen | Commercial ELISA (Technozym) |
| Stratmann et al40 | Germany (10) | iTTP, 8 HUS, 1 Other, 1 | HemosIL AcuStar | Commercial ELISA (Technozym) |
| Toulon et al41 | France (56) | NS | HemosIL AcuStar | FRETS-VWF73 assay |
| Valsecchi et al42 | Italy (127) | iTTP, 100 cTTP, 9 HUS, 7 Other TMA, 11 | HemosIL AcuStar | In-house FRETS-VWF73 assay, commercial ELISA (Technozym) |
DG-EIA, deoxyguanosine enzyme immunoassay; FRETS-VWF73, FRET assay with VWF 73 amino acid peptide; HUS, hemolytic uremic syndrome; NS, not specified.
The listed population (n) is the study population, which may not equal the number of plasma samples evaluated because not all samples were tested in each comparison and some patients provided multiple samples at different time points (eg, during an acute TTP episode and later for ADAMTS13 monitoring).
T. Pitchford, J.J. van Veen, R. Fretwell, and S. Kitchen, unpublished data, June 2024.